Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Philogen SpA ( (IT:PHIL) ) has issued an update.
Philogen S.p.A. announced an update on its share buyback program, revealing the purchase of 7,628 shares between May 12 and May 16, 2025, at an average price of Euro 22.3742 per share, totaling Euro 170,670.65. This move is part of a broader strategy to enhance shareholder value and demonstrates the company’s commitment to its investors. The buyback program, since its inception, has seen the acquisition of 12,152 shares, representing 0.0299% of the share capital, indicating Philogen’s proactive approach in managing its equity and reinforcing its market position.
The most recent analyst rating on (IT:PHIL) stock is a Buy with a EUR25.00 price target. To see the full list of analyst forecasts on Philogen SpA stock, see the IT:PHIL Stock Forecast page.
More about Philogen SpA
Philogen is an Italian-Swiss biotechnology company specializing in the research and development of pharmaceutical products aimed at treating diseases with high mortality rates. The company focuses on creating targeted anti-cancer drugs using high-affinity ligands for tumor markers, employing technologies like Antibody Phage Display Libraries and DNA-Encoded Chemical Libraries. Philogen’s primary therapeutic strategy involves tumor targeting, which selectively delivers potent therapeutic agents to tumors while sparing healthy tissues. The company aims to develop innovative treatments for diseases lacking satisfactory therapies, leveraging proprietary technologies, experience in drug development, and a robust portfolio of patents.
YTD Price Performance: 15.90%
Average Trading Volume: 9,484
Technical Sentiment Signal: Buy
Current Market Cap: €660.9M
Find detailed analytics on PHIL stock on TipRanks’ Stock Analysis page.